Unveiling Alpha-Naphthoflavone Mediated CYP1A2 Suppression and Analysis of Consequent Structural Dynamics

Authors

Zahra Zahid Piracha

Assistant Professor, International Center of Medical Sciences Research (ICMSR), United States of America (USA)

AssociateProfessor, Biocamistry, Clinical and Biomedical Research Centre (CBRC) and Multidisciplinary Lab (MDL), Foundation University School of Health Sciences (FUSH), Foundation University, Islamabad, Pakistan

Naila Azam

Professor, Community Medicine, Foundation University School of Health Sciences (FUSH), Foundation University, Islamabad, Pakistan

Keywords

Alpha-naphthoflavone Cytochrome P450, Computational modeling, CYP1A2, Structural characterization.

Abstract

Background:

Cytochrome P450 enzymes play vital roles in metabolizing drugs, endogenous compounds, and environmental pollutants. Among them, Cytochrome P450 1A2 (CYP1A2), CYP1A1 and CYP1B are particularly important for activating carcinogens. Computational modeling of CYP1A2 is essential for understanding its interactions with various molecules, substrates, and inhibitors.

Objective:

To characterize the structure of CYP1A2 and explore the binding of alpha-naphthoflavone to its active site.

Study Design:

In Silico study (Computational modeling).

Place and Duration of Study:

International Center of Medical Sciences Research (ICMSR), Islamabad, Pakistan.

Material and Methods:

Using the Swiss PDB Viewer, the structural features of CYP1A2 were assessed, focusing on key residues, motifs, helices, and conserved regions.

Results:

Our findings identified specific binding sites for Alpha-Naphthoflavone (ANF), highlighting its potential as a potent inhibitor of CYP1A2. This research contributes to our knowledge of the clinical and toxicological implications associated with CYP1A2.

Conclusion:

Structural differences were found between CYP1A2 and related enzymes, with less than 40% sequence identity compared to several other P450s. The study predominantly compares CYP1A2 with CYP 2A6 and CYP3A4 due to these differences. T he developed structural models offer a fast and precise method for studying CYP1A2, aiding in understanding its role in drug metabolism and toxicology.

How to cite this article

Piracha ZZ, Saeed U, Azam N. Unveiling Alpha-Naphthoflavone Mediated CYP1A2 Suppression and Analysis of Consequent Structural Dynamics. HMDJ. 2024; 04(01): 16-20.

DOI: https://doi.org/10.69884/hmdj.4.1.3590

References

Granfors MT, Backman JT, Neuvonen M, et al. Ciprofloxacin greatly increases concentrations and hypotensive ffect of tizanidine by inhibiting its cytochrome P450 1A2-mediated presystemic metabolism.Clin Pharmacol Ther. 2004;76(6):598–606.
Vasanthanathan P, Taboureau O, Oostenbrink C, et al. lassification of cytochrome P450 1A2 inhibitors and noninhibitors by machine learning techniques. Drug Metabolism and Disposition. 2009; 37 (3) 658-664.
P05177 · CP1A2_HUMAN [Internet].Cambridgeshire(CB): Elixir, Welcome Genome Campus Hixton.[cited 2024 Feb 26]. Available from http://www.uniprot.org/uniprot/P05177.
Nebert DW,Russell DW. Clinical importance of the cytochromes P450. Lancet. 2002; 360(9340):1155-1162.
Xu J. The effect of the new media on increasing female appearance anxiety. J Educ Humanit Soc Sci. 2023;8(2):1373-1377.
Bauer E, Guo Z, Ueng YF Bell, et al, P. Oxidation of benzo[a]pyrene by recombinant human cytochrome P450 enzymes. . Chem Res Toxicol. 1995;8(1):136-42.
Shimada T, Yamazaki H, Foroozesh M, et al. Selectivity of polycyclic inhibitors for human cytochrome P450s 1A1, 1A2, and 1B1. Chem Res Toxicol. 1998;11(9):1048–1056.
Gunes A, Dahl ML. Variation in CYP1A2 activity and its clinical implications: influence of environmental factors and genetic polymorphisms. Pharmacogenomics. 2008;9(5):625–37.
Zhou SF, Wang, B, Yang, LP, et al. Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2. Drug Metab Rev. 2010; 42(2): 268–354.
Ikeya K, Jaiswal AK, Owens RA, et al. Human CYP1A2: sequence, gene structure, comparison with the mouse and rat orthologous gene, and differences in liver 1A2 mRNA expression. Mol Endocrinol. 1989;3(9):1399–1408.
Lewis DF, Lake BG, Dickins M, et al. Homology modelling of human CYP1A2 based on the CYP2C5 crystallographic template structure. Xenobiotica. 2003;33(3):239–254.
Rendic S. Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002;34(1-2):83–448.
Parker AC, Preston T, Heaf D, et al. Inhibition of caffeine metabolism by ciprofloxacin in children with cystic fibrosis as measured by the caffeine breath test. Br J Clin Pharmacol. 1994;38(6):573–576.
Caldwell J. The current status of attempts to predict species differences in drug metabolism. Drug Metab Rev.1981;12(2): 221–237.
Shimizu T, Tateishi T, Hatano M,et al. Probing the role of lysines and arginines in the catalytic function of cytochrome P450d by site-directed mutagenesis. Interaction with NADPH-cytochrome P450 reductase. J Biol Chem. 1991;266(6):3372–3375.
Smith DA, Ackland MJ, Jones BC, et al. Properties of cytochrome P450 isoenzymes and their substrates part 2: properties of cytochrome P450 substrates. Drug Discov Today. 1997;2(11):479 – 486.
Saeed U, Waheed Y, Anwar A, et al . In-Silico Binding of ATP to Protein Kinase C Delta: Insights into the Structure and Active Site. Eur J Sci Res.2011; 52 (2) :177-187.
Liu J, Ericksen SS, Sivaneri M, et al. The effect of reciprocal active site mutations in human cytochromes P450 1A1 and 1A2 on alkoxyresorufin metabolism. Arch Biochem Biophys. 2004;424(1):33–43.
Zhou SF, Yang LP, Zhou ZW, et al. Insights into the substrate specificity, inhibitors, regulation, and polymorphisms and the clinical impact of human cytochrome P450 1A2. APPS J. 2009;11(3):481-494.
Sansen S, Yano JK, Reynald RL, et al. Adaptations for the oxidation of polycyclic aromatic hydrocarbons exhibited by the structure of human P450 1A2. J Biol Chem. 2007;282(19):14348-14355.
Cho US, Park EY, Dong MS, et al. Tight-binding inhibition by α-naphthoflavone of human cytochrome P450 1A2. Biochim Biophys Acta. 2003;1648(1-2):195–202.

PDF